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Original article
Characterizing infection in anti-neutrophil
cytoplasmic antibody–associated vasculitis: results
from a longitudinal, matched-cohort data linkage
study
Shifa H. Sarica1, Neeraj Dhaun 2, Jan Sznajd3, John Harvie3,
John McLaren4, Lucy McGeoch5, Vinod Kumar6, Nicole Amft7, Lars Erwig7,
Angharad Marks8, Corri Black1 and Neil Basu9
Abstract
Objectives. Infection exerts a major burden in ANCA-associated vasculitis (AAV), however, its precise extent and
nature remains unclear. In this national study we aimed to longitudinally quantify, characterize and contextualize in-
fection risk in AAV.
Methods. We conducted a multicentre matched cohort study of AAV. Complementary data on infections were
retrieved via data linkage with the population-based Scottish microbiological laboratory, hospitalization and primary
care prescribing registries.
Results. A total of 379 AAV patients and 1859 controls were followed up for a median of 3.5 years (interquartile
range 1.9–5.7). During follow-up, the proportions of AAV patients with at least one laboratory-confirmed infection,
severe infection and primary care antibiotic prescription were 55.4%, 35.6% and 74.6%, respectively. The risk of
infection was higher in AAV than in matched controls flaboratory-confirmed infections: incidence rate ratio [IRR]
7.3 [95% confidence interval (CI) 5.6, 9.6]; severe infections: IRR 4.4 [95% CI 3.3, 5.7]; antibiotic prescriptions: IRR
2.2 [95% CI 1.9, 2.6]g. Temporal trend analysis showed that AAV patients remained at a higher risk of infections
throughout the follow-up period, especially year 1. Although the Escherichia genus was the most commonly identi-
fied pathogen (16.6% of AAV, 5.5% of controls; P<0.0001), AAV patients had the highest risk for Herpes [IRR
12.5 (95% CI 3.7, 42.6)] and Candida [IRR 11.4 (95% CI 2.4, 55.4)].
Conclusion. AAV patients have up to seven times higher risk of infection than the general population and the
overall risk remains significant after 8 years of follow-up. The testing of enhanced short- to medium-term prophylac-
tic antibiotic regimes should be considered.
Key words: granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic poly-
angiitis, infections, longitudinal study
Rheumatology key messages
. AAV patients experience up to seven times greater risk of infection compared with matched controls.
. This risk is greatest in the first year but persists after 8 years of follow-up.
. The broad range of identified microbes indicates the potential need for broader-spectrum prophylactics.
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Introduction
ANCA-associated vasculitides (AAVs) are a group of
multisystem autoimmune diseases comprising granulo-
matosis with polyangiitis, microscopic polyangiitis
(MPA) and eosinophilic granulomatosis with polyangiitis.
Until the adoption of immunosuppressive therapy in
the 1980s, AAVs were almost always fatal; however,
they are now considered chronic, relapsing diseases
with estimated 5 year survival rates of 80% [1]. Patient
prognosis in AAV remains poor—an observation that is
often attributed to the consequences of drug toxicity,
specifically infections [2–5].
The risk of infections in AAV is considered high; how-
ever, this has yet to be robustly quantified. Studies of
infection in AAV report variable risks ranging from 6 to
67% [6–14]. This wide range is mainly ascribed to di-
verse sampling frames, with many studies focussing on
uncontrolled, highly selected tertiary care populations.
Moreover, different approaches to infection identification
have been employed, with most limited to those result-
ing in hospitalization.
Currently there is no ideal method for assessing infec-
tion risk in a patient population. To attain a thorough
understanding of the infection risk, it is essential to util-
ize complementary approaches involving different levels
of healthcare, such as hospitalizations, microbiological
laboratory records and antibiotic prescriptions, each
measure bringing different methodological strengths
and clinical insights. In Scotland, population-based
healthcare records are routinely collected electronically
and are centralized. Since the records of individuals are
indexed under unique identification numbers, records in
various healthcare registries can be linked. Capitalizing
on this extensive data linkage capacity, in this large,
matched-cohort study we aimed to contextualize infec-
tions in AAV by comparing them with those in the
general population and, uniquely, to characterize infec-
tions in AAV in terms of severity, temporal trends and
causative pathogens.
Methods
Routinely collected healthcare registries and data
linkage in Scotland
National Health Services (NHS) Scotland holds rich
population-based healthcare registries, with almost
complete population coverage [15]. These centralized
registries are routinely linked to follow up individuals
within the healthcare system [16]. In this study we used
the hospital episode data (SMR01), which records infor-
mation on all day-case and inpatient hospitalizations in
Scotland; the Electronic Communication of Surveillance
in Scotland (ECOSS) registry, which collects information
on all positive microbiological test results (from both
primary and secondary care); and the Prescribing
Information System database, which records all medica-
tions dispensed in primary care [17–20]. Data linkage
was conducted by NHS Scotland via deterministic
linkage methods using unique identification numbers.
This process was previously demonstrated to be of
high quality [21, 22].
Governance
The research was approved by the Public Benefit and
Privacy Panel for Health and Social Care, who scrutinize
applications for access to anonymized routine data
(1516-0194/Sarica). Information governance, confidenti-
ality and data protection were undertaken according to
the Data Protection Act (1998). Ethical approval was
granted by the national Scotland ‘A’ Research Ethics
Committee (15/SS/0152).
Study design
We used a matched cohort study using routinely col-
lected health data covering a 9 year period from 1
January 2008 to 28 February 2017. Approval was
received from the Scotland ‘A’ Research Ethics
Committee (reference 15-SS-0152) and the Public
Benefit and Privacy Panel for Health and Social Care
(reference 1516-0194).
AAV cohort
An inception cohort of AAV patients was identified using
the European Medicines Agency criteria in seven hospi-
tals across Scotland [23]. To be eligible, patients were
required to be diagnosed from 1 January 2008 onwards
and be at least 16 years of age at diagnosis. Clinical in-
formation was collected on the date of diagnosis,
including ANCA status and AAV type. The date of AAV
diagnosis was assigned as the index date.
General population controls
NHS Scotland matched each patient with AAV with up
to five general population controls by age (62 years),
sex and geography, i.e. post code. Each patient in the
general population cohort was assigned the same index
date as their corresponding AAV patient.
Follow-up period
Patients were followed from the index date until death
or 28 February 2017, whichever came first. Information
on death was collected through data linkage with the
National Records System Death Registry, which records
all deaths in Scotland [24].
Identifying infections in routinely collected healthcare
registries
Depending on the registry from which they were identi-
fied, infections were categorized as laboratory-
confirmed infections, severe infections or primary care
antibiotics prescriptions. Laboratory-confirmed infections
were identified using free-text records in the ECOSS
registry. Uniquely, this registry contains information on
pathogens identified in microbiological specimens. Only
information on the genus of each identified pathogen
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was feasibly extractable. We excluded pathogens identi-
fied using serological testing, as it was not possible to
distinguish IgG positivity and thus reliably ascertain
whether associated infective events actually occurred
during follow-up. Severe infections were identified in the
hospitalization database using the International
Classification of Diseases, Tenth Revision algorithms
developed by Inada-Kim et al. [25]. These algorithms
were originally developed using administrative datasets
for surveillance of patients with a risk of sepsis. Primary
care antibiotics prescriptions were identified using rele-
vant generic drug names and British National Formulary
(BNF) paragraphs, the professional guidelines used for
prescriptions in Scotland [26]. Details on relevant BNF
paragraphs are available in Supplementary Table S1,
available at Rheumatology online. To account for com-
mon prophylaxis against infections in AAV patients, we
excluded azithromycin, co-trimoxazole and nystatin pre-
scriptions in this analysis.
To minimize misclassification of prolonged infections
as recurrent infections, we assumed that infection or
antibiotics prescribing records within 28 days of each
other represented a continued infection [27]. When
ascertaining laboratory-confirmed infections, we incor-
porated data on causative pathogens as well.
Accordingly, positive test results within 28 days of each
other were considered recurrent infections if they were
due to different pathogens. It was not possible to con-
sider causative pathogens for severe infections and pri-
mary care antibiotic prescriptions, as relevant
information was not available.
Statistical analysis
The proportions of patients developing infections in
each cohort were compared using chi-squared tests.
Overall, infection rates in AAV and controls were com-
pared using multilevel Poisson regression. The multilevel
model introduces a ‘random effect’ that allows the risk
of an event to vary randomly within each patient and
hence permits repeated infections in the same patient to
be independent [28, 29]. Models were adjusted for age
at index, sex and health board of residence to account
for confounding.
Temporal trends analysis was conducted by stratifying
the follow-up time at 30, 90 and 180 days and yearly
afterwards using Lexis expansions [30]. These time
points were selected based on the current treatment
guidelines on the duration of induction and remission
therapy in AAV to provide sufficient granularity to ob-
serve potential temporal changes in the incidence rates
of infections [23]. Infection rates at each interval were
calculated separately by dividing the number of infec-
tions observed in each interval by person-years of
follow-up included in each interval. The 95% CIs were
computed using the Poisson assumption [28]. Incidence
rate ratios (IRRs) comparing the rates at each discrete
interval were calculated by dividing the rate in AAV by
that in the general population. The 95% CIs around
these IRRs were computed using the Byar method [31].
All analyses were performed in Stata version 14
(StataCorp, College Station, TX, USA) [32].
Results
Infections in AAV and general population controls
A total of 379 AAV cases were matched with 1859 gen-
eral population controls. Patients were followed up for a
median of 3.5 years. Baseline patient characteristics are
shown in Table 1. The characteristics of patients
included in the analysis pertaining to antibiotic prescrip-
tion can be found in Supplementary Table S2, available
at Rheumatology online.
The proportions of AAV patients with at least one
laboratory-confirmed infection, severe infection and pri-
mary care antibiotic prescription at follow-up were
55.4%, 35.6% and 74.6%, respectively (Table 2). Over
the duration of the study, AAV patients were more likely
than controls to develop laboratory-confirmed infections
[adjusted IRR 7.3 (95% CI 5.6, 9.6)], develop severe
infections [adjusted IRR 4.4 (95% CI 3.3, 5.7)] and re-
ceive primary care antibiotic prescriptions [adjusted IRR
2.2 (95% CI 1.9, 2.1)]. During follow-up, 35 cases died;
none of these had infection listed as their main cause of
death.
Temporal trends of infections in AAV and general
population controls
AAV patients had the highest rates of laboratory-
confirmed infections and severe infections during the
first year of follow-up, especially during the first 30 days
(Figs 1 and 2). Both the rates of laboratory-confirmed
infections and severe infections fell thereafter; however,
TABLE 1 Patient characteristics at baseline
Characteristics AAV
(n5 379)
Controls
(n5 1859)
Male sex, n (%) 196 (51.7) 965 (51.9)
Age at index, years,
median (IQR)
61.6 (51.3–70.4) 61.5 (51.1–70.2)
Follow-up, years,
median (IQR)
3.5 (1.9–5.7) 3.5 (2.0–5.7)
AAV type, n (%) NA
GPA 205 (54.1)
MPA 131 (34.6)
EGPA 41 (10.8)
Missing 2 (0.5)
ANCA seropositivity,
n (%)
NA
PR3-ANCA 185 (48.8)
MPO-ANCA 149 (39.3)
ANCA negative 43 (11.4)
Missing 2 (0.5)
EGPA: eosinophilic granulomatosis with polyangiitis; GPA:
granulomatosis with polyangiitis; MPA; microscopic polyan-
giitis; PR-3: proteinase-3.
Infection in AAV
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AAV patients remained at a higher risk of both types of
infections than controls throughout follow-up. Although
the difference in the rate of primary care antibiotics pre-
scriptions between AAV and controls was not as substan-
tial as the differences observed with the other metrics,
throughout follow-up AAV patients had a higher rate of
relevant prescriptions than controls (Fig. 3).
Pathogens in AAV and the general population
controls
Sixty-one pathogen types were identified during follow-
up. AAV pathogens commonly involved the urinary tract
(27%), followed by infections identified from the blood
(22.3%) and lower respiratory tract (19.9%)
(Supplementary Table S3, available at Rheumatology
online). The risks of the most frequently observed
pathogens in AAV are reported in Table 3. Results for
rarer infections (n< 5) were not disclosed to preserve
patient confidentiality; note that these included
Pneumocystis jirovecii. Overall, Escherichia was the
most commonly observed genus in both AAV and con-
trols (16.2 vs 5.5%, P<0.001). However, the greatest
disparity in confirmed pathogens between AAV and
controls were for Herpes [IRR 12.5 (95% CI 3.7, 42.6)],
Candida [IRR 11.4 (95% CI 2.4, 55.4)], Clostridium
TABLE 2 Comparing overall infection incidence in AAV and the general population at follow-up
Factor AAV, n (%) Controls,
n (%)
P for v2 test IRR
(unadjusted)
(95% CI)
P for IRR IRR
(adjusted)a
(95% CI)
P for
IRRa
Laboratory-confirmed
infections
210 (55.4) 294 (15.8) <0.0001 6.7 (5.2, 8.6) <0.0001 7.3 (5.6, 9.6) <0.0001
Severe infections 131 (35.6) 202 (10.9) <0.0001 3.8 (2.9, 5.1) <0.0001 4.4 (3.3, 5.7) <0.0001
Primary care antibiotic
prescriptionsb
258 (74.6) 902 (53.0) <0.0001 2.1 (1.7, 2.5) <0.0001 2.2 (1.9, 2.6) <0.0001
General population controls were used as the reference group when calculating IRR.
aAdjusted for age, sex and health board of residence.
bPrimary care prescribing data were available for 2009 onwards, therefore analysis included patients with an index date on
or after 1 January 2009.
FIG. 1 Comparing temporal trends in the rate of laboratory-confirmed infections in AAV and control
The rate in controls was used as the reference when calculating IRR.
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FIG. 2 Comparing temporal trends in the rate of serious infections in AAV and controls
The rate in controls was used as the reference when calculating IRR.
FIG. 3 Comparing temporal trends in the rate of primary care antibiotic prescriptions in AAV and controls
The rate in controls was used as the reference when calculating IRR.
Infection in AAV
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[IRR 9.2 (95% CI 2.7, 30.7)], Enterococcus [IRR 5.3
(95% CI 2.2, 12.4)] and Enterobacter [IRR 5.2 (95% CI
1.0, 14.0)].
Discussion
In this study we are the first to longitudinally quantify
and characterize the infection risk in AAV and compare
it with that in the general population using three comple-
mentary infection measures. Our findings show that AAV
patients are at a high risk of infections: they were seven
times more likely than the general populations to have
laboratory-confirmed events, four times more likely to
develop infections requiring hospitalization and twice as
likely to have been prescribed antibiotics in primary
care. Crucially, our data also indicate that this increased
risk persists in the long term. While Escherichia was the
most common pathogen identified in both AAV and con-
trols, the greatest proportional differences between the
two groups were seen for Herpes, Candida, Clostridium,
Enterococcus and Enterobacter.
Our findings are consistent with previous studies that
have largely focussed on severe infections requiring
hospitalization. For instance, a Swedish study showed
an increased risk of severe infections in AAV compared
with the general population using similar methods [11].
Our long-term assessment of infection risk in AAV is
novel. While several studies agree that the risk of infec-
tion in AAV is greatest early after diagnosis when the
burden of immunosuppression is greatest [33], we are
the first to demonstrate that this risk remains elevated
for several years. It is not uncommon for patients to
remain on immunosuppression for this length of time.
However, a large proportion of patients are completely
weaned off such therapy after 2–5 years and it is inter-
esting to observe similar infection risk ratios from year 3
onwards, suggesting persisting long-term immune dys-
function that may reflect chronic perturbation of the
underlying disease or continued injury from past
immunosuppression (although it is noteworthy that dur-
ing the time frame of this study, rituximab was not com-
monly prescribed in Scotland).
Controlled study designs are crucial in infection epi-
demiology, and here we report the first comparisons of
pathogens between AAV and the general population.
We show that bacterial infections are the most com-
monly observed infections in AAV. Although limited in
number, previous uncontrolled single-centre studies
have indicated the same [7, 12, 13, 34, 35]. The largest
of these studies was by Yang et al. [12], who reviewed
the case notes of 248 AAV patients in China. Of the
87 infections observed within a 15 month period,
Acinetobacter baumannii, Staphylococcus aureus and
Pseudomonas aeruginosa constituted the most
common bacterial pathogens, while Candida albicans
and varicella-zoster virus were the most common fungal
and viral pathogens, respectively. In our study, the most
common bacterial pathogens were Escherichia,
Staphylococcus and Klebsiella, while the most common
viral and fungal pathogens were Herpes and Candida.
Our study excluded episodes of varicella-zoster and
many other viruses detected by Ig testing, as it was
not possible to distinguish IgG from IgM responses.
TABLE 3 Comparing pathogens in AAV and the general population
Infection typea AAV
(n5379),
n (%)
Control
(n5 1859),
n (%)
P for v2
test
IRR
(95% CI)
P for IRR Adjusted IRRc
(95% CI)
P for IRRc
Escherichia 63 (16.6) 102 (5.5) <0.0001 4.9 (3.2, 7.5) <0.0001 4.3 (2.7, 6.9) <0.0001
Staphylococcus 49 (12.9) 64 (3.4) <0.0001 5.1 (3.1, 8.5) <0.0001 5.0 (3.3, 7.5) <0.0001
Klebsiella 26 (6.9 34 (1.8) <0.0001 4.9 (1.7, 14.1) 0.003 4.7 (2.1, 10.6) <0.0001
Haemophilus 23 (6.1) 30 (1.6) <0.0001 4.3 (2.3, 8.1) <0.0001 5.7 (3.3, 10.0) <0.0001
Streptococcus 20 (5.3) 29 (1.6) <0.0001 4.8 (2.7, 8.8) <0.0001 5.5 (3.2 ,9.3) <0.0001
Enterococcus 19 (5.0) 41 (2.2) 0.002 5.3 (2.2, 12.4) <0.0001 6.8 (2.9, 16.0) <0.0001
Candida 9 (2.4) 12 (0.7) 0.001 11.4 (2.4, 55.4) 0.002 NA NA
Enterobacter 8 (2.1) 7 (0.4) <0.0001 5.2 (2.0, 14.0) 0.001 NA NA
Herpesb 7 (1.9) <5 (<0.3)* <0.0001 12.5 (3.7, 42.6) <0.0001 NA NA
Pseudomonas 7 (1.9) 7 (0.4) 0.001 2.0 (0.5, 7.6) 0.326 NA NA
Citrobacter 6 (1.6) <5 (<0.3)* <0.0001 4.8 (1.4, 16.7) 0.014 NA NA
Clostridium 6 (1.6) <5 (<0.3)* <0.0001 9.2 (2.7, 30.7) <0.0001 NA NA
Campylobacter 5 (1.3) 7 (0.4) 0.022 3.4 (1.6, 7.2) 0.002 NA NA
Mycobacterium 5 (1.3) 6 (0.3) 0.011 3.8 (0.8, 17.8) 0.091 NA NA
aInfection types were determined using genus only. Therefore it is not possible to distinguish between different types of
infections of the same genus, e.g. herpes simplex virus infections vs herpes zoster virus infections.
bIncludes all herpes viruses.
cAdjusted for age at index, sex and health board of residence. Infection types are ordered from most to least common
infections in AAV.
*Cell values <5 suppressed in accordance with statistical disclosure process to preserve patient confidentiality.
NA: model adjustment was not applicable due to small numbers.
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The differences in bacterial pathogens between the two
studies may be due to differences in geography and
follow-up times (a median of 3.2 years in our study vs
15 months).
Our study has several important strengths. First, we
used three different methods, each with its advantages,
and identified infections in rich healthcare databases
with almost complete population coverage. In particular,
the largely consistent temporal trends of infection risk
across laboratory-confirmed and severe infections pro-
vide validity to our conclusions. We did not observe a
similar disparity between the earlier rates of primary
care antibiotics prescribing in AAV and the general
population, an observation that most likely reflects the
predominance of hospital-directed management during
the initial post-diagnosis phase.
Several methodological limitations must be consid-
ered when interpreting our findings. Our study was not
entirely population-based. However, we identified AAV
patients from rheumatology and nephrology depart-
ments, the two departments primarily responsible for
managing AAV patients in Scotland, and the sites
involved in our study included teaching and general hos-
pitals from almost every health catchment area in
Scotland, thus the potential impact of selection bias on
our findings is likely minimal. Second, the effect of
potential surveillance bias on the results must also be
considered. Infection among immunosuppressed
patients is a common concern and so clinicians will
have a lower threshold to investigate and treat AAV
patients for this possibility compared with the general
population. This explains some of the contextual dispar-
ity with the general population in regards to the labora-
tory-confirmed infections and antibiotic prescriptions,
although such bias will be a less of an issue for serious
infections. Finally, while data linkage of administrative
databases offers an efficient and cost-effective way to
develop and analyse disease cohorts, researchers with
specific hypotheses are inevitably constrained to the
analysis of variables originally determined for alternative
purposes. For this reason, we were unable to report
potentially interesting data such as numbers of hospital-
acquired infections, immunosuppressant burden, preva-
lence of renal dysfunction and vasculitis relapse.
Even in the absence of quantitative data, physicians
have long been familiar with the risk of infections in
AAV. Indeed, international recommendations for the
management of vasculitis advocate prophylaxis against
infections (specifically co-trimoxazole for P. jirovecii,
which was prescribed to 76% of this cohort) in patients
taking cyclophosphamide and routine checks for hypo-
immunoglobulinaemia prior to each course of rituximab,
as well as vaccination against certain infections, if pos-
sible [33, 36]. Despite these efforts to tackle the infec-
tious burden in AAV, the current study demonstrates
that this risk remains substantial. It is highest immedi-
ately following diagnosis and the spectrum of pathogens
at this time is broad. Moreover, the risk remains signifi-
cantly greater than in the general population, even after
8 years. Taken together, the role of broader-spectrum
antibiotic prophylaxis—at least during the first months—
should be considered. For example, low-dose cepha-
lexin has been safely and effectively used for infection
prophylaxis in other populations [37] and its spectrum of
action is known to target the salient microbes identified
herewith. The gains of such an intervention must be bal-
anced with their toxicity (e.g. higher rates of Clostridium)
and so clinical trials are warranted to complement tar-
geting of modifiable risk factors (e.g. corticosteroids,
dosing regimens) in order to reduce this unacceptable
infection burden.
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